Payment overview · 2025
General Payments
$654.83
37 reported records · 13 companies
Healthcare provider profile · identity verified
Steven R Ross, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLORENCE, SC · NPI 1689647943
Verified facts
What the public records show
CMS Open Payments records show Steven R Ross, MD received $654.83 in general payments during 2025 across 37 reported records.
Novo Nordisk Inc accounted for 32.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Gemtesa, Mounjaro, Nexletol, Ozempic, Rybelsus, Shingrix.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $214.03 | 32.7% | 12 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $95.02 | 14.5% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $64.64 | 9.9% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $60.39 | 9.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.02 | 7.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.32 | 5.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.63 | 4.8% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $20.91 | 3.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.52 | 3.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $16.41 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.66 | 2.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.34 | 2.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.94 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $654.83 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $135.47 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $95.02 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.95 | 5 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $64.64 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $60.39 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $52.02 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.87 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 94 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 35 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
94 | 94 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
35 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
306 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
171 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
43 | 42 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 594 | 133 |
| Atorvastatin Calcium | Atorvastatin Calcium | 591 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 489 | 98 |
| Losartan Potassium | Losartan Potassium | 417 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 394 | 87 |
| Ezetimibe | Ezetimibe | 375 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 370 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 334 | 82 |
| Spironolactone | Spironolactone | 316 | 77 |
| Jardiance | Empagliflozin | 306 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 274 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 59 |
| Gabapentin | Gabapentin | 246 | 48 |
| Furosemide | Furosemide | 194 | 45 |
| Trazodone Hcl | Trazodone Hcl | 193 | 36 |
| Lorazepam | Lorazepam | 182 | 44 |
| Sertraline Hcl | Sertraline Hcl | 172 | 39 |
| Eliquis | Apixaban | 171 | 27 |
| Omeprazole | Omeprazole | 164 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 41 |
| Montelukast Sodium | Montelukast Sodium | 143 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 132 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 110 | 26 |
| Xarelto | Rivaroxaban | 106 | 17 |
| Methylprednisolone | Methylprednisolone | 100 | 67 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 99 | 25 |
| Metformin Hcl | Metformin Hcl | 95 | 24 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 94 | 94 |
| Potassium Chloride | Potassium Chloride | 93 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 18 |
| Finasteride | Finasteride | 86 | 20 |
| Mirtazapine | Mirtazapine | 83 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 18 |
| Chlorthalidone | Chlorthalidone | 82 | 18 |
| Lisinopril | Lisinopril | 82 | 17 |
| Meloxicam | Meloxicam | 82 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 19 |
| Ozempic | Semaglutide | 77 | suppressed |
| Synthroid | Levothyroxine Sodium | 75 | 16 |
| Prednisone | Prednisone | 71 | 30 |
| Tramadol Hcl | Tramadol Hcl | 69 | 27 |
| Alprazolam | Alprazolam | 67 | 16 |
| Ramipril | Ramipril | 67 | 16 |
| Alendronate Sodium | Alendronate Sodium | 66 | 14 |
| Allopurinol | Allopurinol | 65 | 13 |
| Meclizine Hcl | Meclizine Hcl | 62 | 25 |
| Simvastatin | Simvastatin | 61 | 12 |
| Cephalexin | Cephalexin | 60 | 44 |
| Ondansetron Odt | Ondansetron | 59 | 34 |
| Trulicity | Dulaglutide | 59 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 55 | suppressed |
| Testosterone | Testosterone | 55 | 11 |
| Celecoxib | Celecoxib | 52 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 43 |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 11 |
| Eplerenone | Eplerenone | 49 | 12 |
| Januvia | Sitagliptin Phosphate | 49 | 13 |
| Bumetanide | Bumetanide | 46 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 13 |
| Aripiprazole | Aripiprazole | 45 | 13 |
| Lansoprazole | Lansoprazole | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | 12 |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 43 | 42 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 41 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 30 |
| Metformin Hcl Er | Metformin Hcl | 41 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 41 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Rybelsus | Semaglutide | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 11 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Sotalol | Sotalol Hcl | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Famotidine | Famotidine | 36 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 35 | 29 |
| Dutasteride | Dutasteride | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 16 |
| Fluconazole | Fluconazole | 32 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 12 |
| Gemtesa | Vibegron | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 12 |
| Estradiol | Estradiol | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 22 |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 24 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 21 |
| Dofetilide | Dofetilide | 24 | suppressed |
| Indapamide | Indapamide | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 17 |
| Azithromycin | Azithromycin | 23 | 19 |
| Teriparatide | Teriparatide | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 16 |
| Baclofen | Baclofen | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Oxycontin | Oxycodone Hcl | 18 | suppressed |
| Dulera | Mometasone/Formoterol | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nexletol | Bempedoic Acid | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Budesonide Dr | Budesonide | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fetzima | Levomilnacipran Hcl | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Protonix | Pantoprazole Sodium | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $654.83 · 37 records | Novo Nordisk Inc | ABRYSVO, AREXVY, Auvelity, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, FREESTYLE LIBRE 3, GEMTESA, MOUNJARO, NEXLETOL, NUPLAZID, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Esperion Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error